The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Mechanisms of drug inhibition of signalling molecules
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“This novel binding mode seemed to confer desirable properties, such as enhanced selectivity relative to ATP-mimetic inhibitor”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Self-citationDNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Self-citationProtein kinase activity associated with the avian sarcoma virus src gene product.
Collett, M. S., & Erikson, R. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.4.2021 · Cited by 1,105
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Identification of a transformation-specific antigen induced by an avian sarcoma virus
BRUGGE, J. S., & ERIKSON, R. L. (1977) · Nature · doi:10.1038/269346a0 · Cited by 888
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation
Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., & Goldsmith, E. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80351-7 · Cited by 729
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Levinson, A. D., Oppermann, H., Levintow, L., Varmus, H. E., & Bishop, J. M. (1978) · Cell · doi:10.1016/0092-8674(78)90024-7 · Cited by 653
Heinrich, M. C., Blanke, C. D., Druker, B. J., & Corless, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1692 · Cited by 634
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Self-citationFDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
Herbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
(2003) · PubMed · Cited by 523
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
Structural basis of inhibitor selectivity in MAP kinases
Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., & Goldsmith, E. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00113-0 · Cited by 423
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8234 · Cited by 303
Wilhelm, S., & Chien, D.-S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393026 · Cited by 289
Shimizu, A., O'Brien, K. P., Sjöblom, T., et al. (1999) · PubMed · Cited by 289
Adams, J. A. (2003) · Biochemistry · doi:10.1021/bi020617o · Cited by 233
Gum, R. J., McLaughlin, M. M., Kumar, S., Wang, Z., Bower, M. J., Lee, J. C., Adams, J. L., Livi, G. P., Goldsmith, E. J., & Young, P. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15605 · Cited by 229
Johnson, J. R., Cohen, M., Sridhara, R., Chen, Y.-F., Williams, G. M., Duan, J., Gobburu, J., Booth, B., Benson, K., Leighton, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0790 · Cited by 219
Ebos, J. M. L., Bocci, G., Man, S., Thorpe, P. E., Hicklin, D. J., Zhou, D., Jia, X., & Kerbel, R. S. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.315.2.6 · Cited by 211
Gilliland, D. G., & Griffin, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00003 · Cited by 202
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
Nelson, M. H., & Dolder, C. R. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g387 · Cited by 192
Targeted CML therapy: controlling drug resistance, seeking cure
O’Hare, T., Corbin, A. S., & Druker, B. J. (2006) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.11.002 · Cited by 178
Human members of the eukaryotic protein kinase family
Kostich, M. S., English, J. M., Madison, V., Gheyas, F., Wang, L., Qiu, P., Greene, J. R., & Laz, T. M. (2002) · Genome biology · doi:10.1186/gb-2002-3-9-research0043 · Cited by 125
Self-citationAnti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Yeon, C. H., & Pegram, M. D. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2899-8 · Cited by 101
Targeting angiogenesis in cancer: clinical development of bevacizumab
Kerr, R. S. (2004) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0026 · Cited by 98
Goldberg, R. M., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1728 · Cited by 90
Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy
Wallace, E. M., Lyssikatos, J. P., Yeh, T. C., Winkler, J. D., & Koch, K. M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507723 · Cited by 70
Downward, J. (2006) · Nature · doi:10.1038/439274a · Cited by 64
A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040
Wangab, Y., Becelaere, K. V., Jiang, P., Przybranowski, S. A., Omer, C. A., & Sebolt, J. S. (2005) · Neoplasia · doi:10.1593/neo.04532 · Cited by 53
Sheinerman, F. B., Giraud, E., & Laoui, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.074 · Cited by 44
Cited by
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Brunk, E., & Rothlisberger, U. (2015) · Chemical Reviews · doi:10.1021/cr500628b · Cited by 494
Metadata
- Authors
- Sebolt-Leopold, J. S., & English, J. M.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 457-462
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2037587486
- Cited by
- 304
- References
- 57
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.